Japanese Regulator Approves GSK’s Benlysta as Add-on Lupus Treatment
Japan’s Ministry of Health, Labor and Welfare has approved Benlysta (belimumab) as an add-on therapy to treat adult patients with systemic lupus erythematosus (SLE) who cannot receive or don’t respond to existing therapies. The drug, developed by GlaxoSmithKline (GSK), will be available in two formulations, given via intravenous (IV) or subcutaneous (SC)…